

1. Record Nr.	UNINA9910139555703321
Autore	Irving Peter
Titolo	Clinical Dilemmas in Inflammatory Bowel Disease [[electronic resource]] : New Challenges
Pubbl/distr/stampa	Hoboken, : Wiley, 2011
ISBN	1-283-24049-1 9786613240491 1-4443-4257-6 1-4443-4254-1
Edizione	[2nd ed.]
Descrizione fisica	1 online resource (286 p.)
Altri autori (Persone)	SiegelCorey A RamptonDavid ShanahanFergus
Disciplina	616.344
Soggetti	Clinical dilemmas Inflammatory bowel diseases Inflammatory Bowel Diseases Inflammatory bowel diseases - Decision making Inflammatory bowel diseases -- Decision making Intestinal Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Diseases Medicine Health & Biological Sciences Gastroenterology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di contenuto	Clinical Dilemmas inInflammatoryBowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD-

Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD- passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment
8 Prebiotics and synbiotics: panacea or placebo
9 Worms: light at the end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids
17 Steroids in Crohn's disease: do the benefits outweigh the dangers? Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use?
26 What is the role of biologics in UC? 27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions
34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis? 35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease
41 Does anti-TNF therapy increase the risk of complications of surgery?

Sommario/riassunto

The second edition of *Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges*, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking
